CLDX Q3 2019 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$546,000-42.0% YoY

Gross Profit

-$11M-1933.2% margin

Operating Income

-$12M-2169.2% margin

Net Income

-$11M-2090.3% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

-23.6%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$707,000

Balance Sheet

Total Assets

$132M

Total Liabilities

$30M

Stockholders' Equity

$101M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$546,000	$941,000	-42.0%
Gross Profit	-$11M	-$11M	+3.8%
Operating Income	-$12M	-$8M	-52.6%
Net Income	-$11M	-$7M	-57.6%

Revenue Segments

Grant

$491,00090%

Service

$55,00010%